IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Assessing options in hot ADC space
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
